Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (YLAKLTALV) Complex Protein (Monomer, MALS verified)

Among the nonvirion proteins of the vaccinia virus (VACV), a 94-kDa long protein is most abundantly present; the protein is a truncated form of the 150-kDa A-type inclusion (ATI) protein of the cowpox virus encoded by the ati gene. This VACV protein does not form intracellular ATIs, being as it is a major immunogen upon infection/immunization of humans or animals with the VACV. variants demonstrated that the mutant LIVPΔati elicits a stronger protective response compared to the parent LIVP. The human HLA-A*0201 Vaccinia virus G5R (YLAKLTALV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and YLAKLTALV peptide of the vaccinia virus.

Biotinylated Human HLA-A*02:01&B2M&Vaccinia virus (YLAKLTALV) Complex Protein is produced by co-expression of HLA and B2M loaded with Vaccinia virus peptide. This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 36.3 kDa and 11.7 kDa. The protein migrates as 38-41 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

● -20°C to -70°C for 12 months in lyophilized state; ● -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Biotinylated Human HLA-A0201 & B2M & Vaccinia virus (YLAKLTALV) Complex Protein (Cat. No. HLR-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-1 ng/mL (QC tested).